Many children receive attention-deficit hyperactivity disorder (ADHD) medication, but factors that determine medication prescription are largely unknown. This study aimed to determine the relative impact of factors on the child, family and general practitioner (GP) practice level on ADHD medication prescription. We included 1259 Dutch children aged 6–18 years with a diagnostic code of ADHD or related behavioural problems (ICPC codes P20-P22) in NIVEL primary care database. Using multilevel analyses, we examined predictors of ADHD medication prescription. Children diagnosed as ‘hyperactive’ were 16 times more likely to be prescribed ADHD medication than those with ‘behavioural concerns’. Children with a parent or sibling receiving ADHD medication were three to four times more likely to be prescribed ADHD medication themselves. Children from GP practices with a high percentage of children with ADHD were twice as likely to be prescribed ADHD medication. Concluding, factors on the individual, family and GP practice level determine ADHD medication prescription. Future research into the decision-making process for ADHD medication is warranted.
Al-HaidarFA (2008) Parental attitudes toward the prescription of psychotropic medications for their children. Journal of Family and Community Medicine15: 35–42.
2.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Association.
3.
AshtonHGallagherPMooreB (2006) The adult psychiatrist’s dilemma: psychostimulant use in attention deficit/hyperactivity disorder. Journal of Psychopharmacology20: 602–610.
4.
BronfenbrennerU (1979) The Ecology of Human Development: Experiments by Nature and Design. Cambridge: Harvard University Press.
5.
BruchmüllerKMargrafJSchneiderS (2012) Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. Journal of Consulting and Clinical Psychology80: 128–138.
6.
ChenCYGerhardTWintersteinAG (2009) Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology19: 187–195.
7.
ChenCYYehHHChenKH. (2011) Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology21: 265–273.
8.
ChilakamarriJKFilkowskiMMGhaemiSN (2011) Misdiagnosis of bipolar disorder in children and adolescents: a comparison with ADHD and major depressive disorder. Annals of Clinical Psychiatry23: 25–29.
9.
CuffeSPMooreCGMcKeownRE (2005) Prevalence and correlates of ADHD symptoms in the national health interview survey. Journal of Attention Disorders9: 392–401.
10.
DerksEMHudziakJJBoomsmaDI (2007) Why more boys than girls with ADHD receive treatment: a study of Dutch twins. Twin Research and Human Genetics10: 765–770.
11.
EvansWNMorrillMSParenteST (2010) Measuring inappropriate medical diagnosis and treatment in survey data: the case of ADHD among school-age children. Journal of Health Economics29: 657–673.
12.
FaberAKalverdijkLJde Jong van den BergLT. (2006) Parents report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care. Journal of Child and Adolescent Psychopharmacology16: 432–440.
13.
FliersEABuitelaarJKMarasA. (2013) ADHD is a risk factor for overweight and obesity in children. Journal of Developmental and Behavioral Pediatrics34: 566–574.
14.
GrahamJBanaschewskiTBuitelaarJ. (2011) European guidelines on managing adverse effects of medication for ADHD. European Child and Adolescent Psychiatry20: 17–37.
15.
GroenmanAPOosterlaanJRommelseNN. (2013) Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. British Journal of Psychiatry203: 112–119.
16.
HjernAWeitoftGRLindbladF (2010) Social adversity predicts ADHD-medication in school children: a national cohort study. Acta Paediatrica99: 920–924.
17.
HodgkinsPSasaneRMeijerWM (2011) Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clinical Therapeutics33: 188–203.
18.
JensenPSArnoldLESwansonJM. (2007) 3-year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry46: 989–1002.
19.
KjeldsenBVJensenSOMunk-JorgensenP (2012) Increasing number of incident ADHD cases in psychiatric treatment. Acta Psychiatrica Scandinavica126: 151–152.
20.
LambertsHWoodM (2002) The birth of the International Classification of Primary Care (ICPC). Serendipity at the border of Lac Leman. Family Practice19: 433–435.
21.
MarcovitchH (2004) Use of stimulants for attention deficit hyperactivity disorder: AGAINST. British Medical Journal329: 908–909.
22.
Netherlands Institute for Health Services Research (2014) NIVEL Zorgregistraties Eerstelijn [NIVEL Primary Care Database]. Available at: http://www.nivel.nl/NZR/zorgregistraties-eerstelijn (accessed 30 November 2015).
23.
NielenMMSchellevisFGVerheijRA (2009) Inter-practice variation in diagnosing hypertension and diabetes mellitus: a cross-sectional study in general practice. BMC Family Practice10: 6.
24.
OhlssonHVervloetMvanDL (2011) Practice variation in a longitudinal perspective: a multilevel analysis of the prescription of simvastatin in general practices between 2003 and 2009. European Journal of Clinical Pharmacology67: 1205–1211.
25.
ReyJMSawyerMG (2003) Are psychostimulant drugs being used appropriately to treat child and adolescent disorders?British Journal of Psychiatry182: 284–286.
26.
SaxLKautzKJ (2003) Who first suggests the diagnosis of attention-deficit/hyperactivity disorder?Annals of Family Medicine1: 171–174.
27.
SchachterHMPhamBKingJ. (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Canadian Medical Association Journal165: 1475–1488.
28.
SciuttoMJEisenbergM (2007) Evaluating the evidence for and against the overdiagnosis of ADHD. Journal of Attention Disorders11: 106–113.
29.
ShawMHodgkinsPCaciH. (2012) A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Medicine10: 99.
30.
SteinMASarampoteCSWaldmanID. (2003) A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics112: e404.
31.
Stichting Farmaceutische Kengetallen (2012) Gebruik ADHD medicatie niet in te dammen [Use of ADHD medication cannot be stopped]. Pharmaceutisch weekblad, p. 147.
32.
UrbanKRGaoWJ (2015) Evolution of the study of methylphenidate and its actions on the adult versus juvenile brain. Journal of Attention Disorders19: 603–619.
33.
VisserSNDanielsonMLBitskoRH. (2014) Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. Journal of the American Academy of Child and Adolescent Psychiatry53: 34–6 e32.
34.
WHO (2011) Guidelines for ATC Classification and DDD Assignment. Oslo: WHO.
35.
WigalSB (2009) Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs23(Suppl 1): 21–31.
36.
WillcuttEG (2012) The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics9: 490–499.
37.
WintersteinAGGerhardTShusterJ. (2008) Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in medicaid database. The Annals of Pharmacotherapy42: 24–31.
38.
WittkampfLCSmeetsHMKnolMJ. (2010) Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Social Psychiatry and Psychiatric Epidemiology45: 819–826.
39.
ZuidgeestMGvanDLSpreeuwenbergP. (2009) What drives prescribing of asthma medication to children? A multilevel population-based study. Annals of Family Medicine7: 32–40.
40.
ZwirsBWBurgerHBuitelaarJK. (2006) Ethnic differences in parental detection of externalizing disorders. European Child and Adolescent Psychiatry15: 418–426.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
